Novo Nordisk v. Meitheal Pharmaceuticals — Dismissed Without Prejudice
Novo Nordisk Inc. and Novo Nordisk A/S brought a patent infringement action against Meitheal Pharmaceuticals and Nanjing King-friend Biochemical Pharmaceutical Co. in Delaware District Court over two pharmaceutical patents. The case was resolved by stipulated dismissal without prejudice in just 62 days.
Pharmaceutical patent dispute exits Delaware in under three months
On 20 October 2023, Novo Nordisk Inc. and Novo Nordisk A/S filed a patent infringement action in the Delaware District Court against Meitheal Pharmaceuticals Inc. and Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. The complaint asserted two patents — US9265893B2 and US8114833B2 — in connection with the Meitheal product. The case was assigned to Judge Colm F. Connolly and prosecuted on the plaintiffs' side by Morris, Nichols, Arsht & Tunnell LLP.
The recorded basis of termination is 'Dismissed without Prejudice'; the docket order is styled as a Stipulation and Order of Dismissal. The case closed on 21 December 2023, just 62 days after filing. A dismissal without prejudice means neither party has obtained a merits adjudication, and the plaintiff retains the legal right to refile the same claims. The specific terms underlying the stipulation are not disclosed in the available record.
A 62-day lifespan — from filing to stipulated dismissal — is notably short even for ANDA-adjacent pharmaceutical litigation, suggesting that the parties reached an accommodation quickly. What drove that rapid resolution, and whether any commercial arrangement accompanied the dismissal, is not disclosed in the public record. The absence of prejudice to refiling means the asserted patents remain live enforcement tools for Novo Nordisk.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 62 days
62 days — a notably short lifespan for a pharmaceutical patent infringement action in Delaware
US9265893B2 & US8114833B2 — Novo Nordisk pharmaceutical patents
Generic pharmaceutical manufacturers, API suppliers, and formulators working in therapeutic categories covered by Novo Nordisk's portfolio should consider both US9265893B2 and US8114833B2 as active FTO concerns. The without-prejudice dismissal in this case means neither patent has been invalidated or found not infringed — they remain fully enforceable against any party whose product falls within the claims.
Official order — verbatim text
The docket records a Stipulation and Order of Dismissal as the closing instrument, with the recorded basis of termination being dismissal without prejudice. This phrasing confirms that no judicial finding on infringement or patent validity was reached. Neither party is bound by a merits ruling, and Novo Nordisk retains the right to refile. The absence of any cost award or prejudice qualifier leaves the IP risk landscape unchanged for market participants.
Dismissed without prejudice: what the stipulated exit means for both parties
Stipulated dismissal without prejudice — no merits ruling
A dismissal without prejudice entered by stipulation means both parties agreed to exit the litigation without a court ruling on the merits. No finding of infringement, validity, or invalidity was made. Crucially, the plaintiff is not barred from refiling the same claims — the asserted patents remain available for future enforcement. The specific terms that led the parties to stipulate are not disclosed in the public record.
No merits adjudicationNovo Nordisk retains full enforcement rights on both patents
Because the dismissal is without prejudice, Novo Nordisk Inc. and Novo Nordisk A/S are legally free to reassert US9265893B2 and US8114833B2 against Meitheal or other generic challengers in future proceedings. The patents have not been adjudicated invalid or not infringed. This outcome preserves optionality for the Novo Nordisk portfolio, though the absence of a merits ruling also means no judicial validation of the patents' strength.
Enforcement rights preservedMeitheal avoids a merits ruling but faces potential re-litigation
Meitheal Pharmaceuticals and Nanjing King-friend exit this action without an adverse infringement finding. However, a without-prejudice dismissal provides no defensive shelter: the same patents can be re-asserted at any time within the applicable statute of limitations. Defendants obtain no formal finding of non-infringement or invalidity that they could invoke in future proceedings. Any broader commercial resolution between the parties is not disclosed in the available record.
No invalidity findingPatents stay in play for generic market entry disputes
In pharmaceutical patent litigation, a without-prejudice exit this early in proceedings typically suggests the parties resolved an immediate commercial question without settling the underlying IP. Both asserted patents — US9265893B2 and US8114833B2 — remain active enforcement tools. Companies developing or commercialising products in the same therapeutic space should monitor Novo Nordisk's enforcement posture, as the patents have not been tested on the merits.
Active enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Meitheal Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Travis J. Murray | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Novo Nordisk, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the pharmaceutical patent enforcement space
Forward-looking IP intelligence derived from Novo Nordisk's enforcement of US9265893B2 and US8114833B2 against Meitheal Pharmaceuticals and Nanjing King-friend.
Novo Nordisk's US patent filing activity in the asserted therapeutic area
Novo Nordisk's assertion of two patents from different application vintages (US11/435977 and US12/525976) suggests layered portfolio coverage in the relevant therapeutic domain. Mapping Novo Nordisk's full US filing activity around these application families can reveal continuation, divisional, or CIP applications that may extend the effective protection window beyond the asserted patents.
Portfolio depth signalPatent filing trends in the Meitheal product technology domain
The involvement of a Chinese API manufacturer (Nanjing King-friend) alongside a US generic filer suggests the asserted technology sits within a competitive generics supply chain. Tracking patent filing trends in this product category — including biosimilar and small-molecule formulation filings — can identify where the competitive landscape is most contested and where white space may exist.
Competitive landscapeMeitheal Pharmaceuticals' patent and regulatory filing activity
As a generic pharmaceutical entrant, Meitheal Pharmaceuticals' ANDA filings and any associated patent certifications signal which innovator compounds it is targeting for market entry. Understanding Meitheal's regulatory pipeline alongside its co-defendant Nanjing King-friend's manufacturing patent activity provides a forward-looking view of where future disputes may arise.
Generic entrant signalsAdjacent formulation R&D opportunities near the asserted patent claims
With US9265893B2 and US8114833B2 covering specific formulation or compound claims, design-around R&D opportunities may exist in adjacent delivery mechanisms, dosing regimens, or excipient combinations not captured by the current claim scope. Identifying claim boundaries and citation networks around these patents can surface patentable white space for competitors and innovators alike.
Design-around opportunitySimilar pharmaceutical patent cases in Delaware District Court
Explore comparable pharmaceutical patent infringement actions dismissed or resolved in Delaware District Court, including cases involving generic entrants and multi-defendant supply chain strategies.
What this case signals for the pharmaceutical patent IP landscape
A 62-day stipulated exit in Delaware pharmaceutical patent litigation carries forward-looking signals for generic entrants and portfolio holders alike.
Without-prejudice exit preserves Novo Nordisk's litigation optionality
US9265893B2 and US8114833B2 remain unlitigated on the merits. Novo Nordisk can refile against Meitheal or any other party. Generic challengers in this space should treat both patents as live enforcement risks and consider pre-emptive validity analysis before advancing to market.
62-day case closure is a red flag for early commercial accommodation
Pharmaceutical patent disputes in Delaware rarely close in under 90 days without some form of accommodation. The speed of this exit — before any substantive motion practice — suggests the parties may have reached an understanding quickly, though the specific terms are not in the public record.
Novo v Meitheal — key questions answered
The case was dismissed without prejudice pursuant to a Stipulation and Order of Dismissal. No merits ruling on infringement or patent validity was issued. The case closed on 21 December 2023, 62 days after filing. The specific terms underlying the stipulation are not disclosed in the public record.
Novo Nordisk asserted two patents: US9265893B2 (application no. US12/525976) and US8114833B2 (application no. US11/435977). Both were asserted together in the infringement action filed in the Delaware District Court on 20 October 2023.
A dismissal without prejudice means Novo Nordisk retains the full legal right to refile the same claims against Meitheal or other parties. Neither US9265893B2 nor US8114833B2 has been found invalid or not infringed. The patents remain active and enforceable, and the dismissal provides no defensive benefit to defendants in future proceedings.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. was named as a co-defendant, which is consistent with a supply chain enforcement strategy targeting both the US generic filer and the foreign manufacturer or API supplier. The specific basis for naming Nanjing King-friend is not further detailed in the available public record.
Yes. Because the dismissal is without prejudice, Novo Nordisk is not barred from refiling the same patent infringement claims against Meitheal Pharmaceuticals or Nanjing King-friend within the applicable limitations period. No judicial finding binds either party on the merits of the underlying IP dispute.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.